{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:32:02Z","timestamp":1761975122402},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s10147-009-0883-6","type":"journal-article","created":{"date-parts":[[2009,10,24]],"date-time":"2009-10-24T01:21:24Z","timestamp":1256347284000},"page":"397-401","source":"Crossref","is-referenced-by-count":23,"title":["Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan"],"prefix":"10.1007","volume":"14","author":[{"given":"Yoshihiro","family":"Shibata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ariyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Takii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taito","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Mitsugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanji","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kusaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,25]]},"reference":[{"key":"883_CR1","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A. Gramont De","year":"2000","unstructured":"De Gramont A, Figer A, Seynour M, et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 18:2938\u20132947","journal-title":"J Clin Oncol"},{"key":"883_CR2","first-page":"275","volume":"23","author":"G. RM","year":"2004","unstructured":"Goldberg RM, Sargent D, Morton RF, et al. (2004) N9741: FOLFOX (oxaliplatin (Oxal)\/5-FU\/leukovorin (LV)) or reduced dose R-Ifl(CPT-11 + 5-FU\/LV) in advanced colorectal cancer (CRC): final efficacy data from an Intergroup Study. J Clin Oncol 23:275 (Suppl; abstract 3621)","journal-title":"J Clin Oncol"},{"key":"883_CR3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3816\/CCC.2006.n.044","volume":"6","author":"P. Tvagi","year":"2006","unstructured":"Tvagi P, Grothey A (2006) Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. Clin Colorectal Cancer 6:261\u2013264","journal-title":"Clin Colorectal Cancer"},{"key":"883_CR4","first-page":"2243","volume":"50","author":"T. Andre","year":"2004","unstructured":"Andre T, Boni C, Mounedji-Boudiaf L, et al. (2004) Multicenter international study of oxaliplatin\/5-fluorouracil\/leukovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators: oxaliplatin, fluorouracil and leukovorin as adjuvant treatment for colon cancer. N Engl J Med 50:2243\u20132251","journal-title":"N Engl J Med"},{"key":"883_CR5","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/cncr.11379","volume":"97","author":"R.R. Thomas","year":"2003","unstructured":"Thomas RR, Quinn MG, Schuler B, et al. (2003) Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 97:2301\u20132307","journal-title":"Cancer"},{"key":"883_CR6","first-page":"2590","volume":"17","author":"S.W. Siu","year":"2006","unstructured":"Siu SW, Chan RT, Au GK (2006) Hypersensitivity reactions to oxaliplatin:experience in a single institute. Ann Oncol 17:2590\u20132261","journal-title":"Ann Oncol"},{"key":"883_CR7","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.ejca.2005.06.021","volume":"41","author":"F. Maindrault-Goebel","year":"2005","unstructured":"Maindrault-Goebel F, Andre T, Tournigand C, et al. (2005) Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 41:2262\u20132267","journal-title":"Eur J Cancer"},{"key":"883_CR8","first-page":"1671","volume":"18","author":"A. Gowda","year":"2004","unstructured":"Gowda A, Goel R, Berdzik J, et al. (2004) Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology 18: 1671\u20131675","journal-title":"Oncology"},{"key":"883_CR9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.bjc.6601155","volume":"89","author":"G. Brandi","year":"2003","unstructured":"Brandi G, Pantaleo MA, Galli C, et al. (2003) Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 89:477\u2013481","journal-title":"Br J Cancer"},{"key":"883_CR10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00689458","volume":"35","author":"A.A. Shleback","year":"1995","unstructured":"Shleback AA, Clark PI, Green JA, et al. (1995) Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemother Pharmacol 35:349\u2013351","journal-title":"Cancer Chemother Pharmacol"},{"key":"883_CR11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00000421-200212000-00020","volume":"25","author":"C. Koren","year":"2002","unstructured":"Koren C, Yerushalmi R, Katz A, et al. (2002) Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol 25:625\u2013626","journal-title":"Am J Clin Oncol"},{"key":"883_CR12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s101470200056","volume":"7","author":"R. Basu","year":"2002","unstructured":"Basu R, Rajkumar A, Datta NR (2002) Anaphylaxis to cisplatin following nine previous uncomplicated cycles. Int J Clin Oncol 7:365\u2013367","journal-title":"Int J Clin Oncol"},{"key":"883_CR13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000055363","volume":"61","author":"A. Polyzos","year":"2001","unstructured":"Polyzos A, Tsavaris N, Kosmas C, et al. (2001) Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 61:129\u2013133","journal-title":"Oncology"},{"key":"883_CR14","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2001.19.12.3126","volume":"19","author":"K.M. Zanotti","year":"2001","unstructured":"Zanotti KM, Rybicki LA, Kennedy AW, et al. (2001) Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 19:3126\u20133129","journal-title":"J Clin Oncol"},{"key":"883_CR15","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1023\/A:1011161126611","volume":"12","author":"M. Stahl","year":"2001","unstructured":"Stahl M, Koster W, Wikle H (2001) Reaction after oxaliplatin \u2014 prevention with corticosteroids? Ann Oncol 12:874","journal-title":"Ann Oncol"},{"key":"883_CR16","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/0959-8049(94)90489-8","volume":"30","author":"J.S. Morgan","year":"1994","unstructured":"Morgan JS, Adams M, Mason MD (1994) Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer 30:1205\u20131206","journal-title":"Eur J Cancer"},{"key":"883_CR17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1023\/A:1008366223918","volume":"12","author":"D. Santini","year":"2001","unstructured":"Santini D, Tonini G, Salerno A, et al. (2001) Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol 12:132\u2013133","journal-title":"Ann Oncol"},{"key":"883_CR18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1164\/ajrccm.160.2.9807065","volume":"160","author":"A.J. Newman Taylor","year":"1999","unstructured":"Newman Taylor AJ, Cullinan P, Lympany PA, et al. (1999) Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts. Am J Respir Crit Care Med 160: 435\u2013438","journal-title":"Am J Respir Crit Care Med"},{"key":"883_CR19","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","volume":"17","author":"M. Markmen","year":"1999","unstructured":"Markmen M, Kennedy A, Webster K, et al. (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17: 1141\u20131145","journal-title":"J Clin Oncol"},{"key":"883_CR20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1048-891x.2005.14401.x","volume":"15","author":"S. Sliesoraitis","year":"2005","unstructured":"Sliesoraitis S, Chikhale PJ (2005) Carboplatin hypersensitivity. Int J Gynecol Cancer 15:13\u201318","journal-title":"Int J Gynecol Cancer"},{"key":"883_CR21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00520-006-0107-9","volume":"15","author":"M.Y. Lee","year":"2007","unstructured":"Lee MY, Yang MH, Liu JH (2007) Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer 15:89\u201393","journal-title":"Support Care Cancer"},{"key":"883_CR22","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1345\/aph.1E532","volume":"39","author":"L. Mis","year":"2005","unstructured":"Mis L, Fernando NH, Hurwitz HI, et al. (2005) Successful desensitization to oxaliplatin. Ann Pharmacother 39:966\u2013969","journal-title":"Ann Pharmacother"},{"key":"883_CR23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","volume":"24","author":"C. Tournigand","year":"2006","unstructured":"Tournigand C, Cervantes A, Figer A, et al. (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer \u2014 a GERCOR study. J Clin Oncol 24:394\u2013400","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-009-0883-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-009-0883-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-009-0883-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T20:24:51Z","timestamp":1559161491000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-009-0883-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["883"],"URL":"https:\/\/doi.org\/10.1007\/s10147-009-0883-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}